Name: Latest research reports of Birla Corporation Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Birla Corporation Ltd.
Rating: 5
Author: Axis Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	27 May 2023	Birla Corporation	Axis Direct Target	1057.40	1111.00	1010.15 (4.68%)	Target met	Buy	pdf post cache	Broker Report Pick of the Week:29 May 2023 Axis Direct We recommend a BUY on the stock for a target price of Rs1111/ implying an upside of 10% from CMP pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	Motilal Oswal Target	1744.80	1160.00	969.90 (79.89%)	Target met	Buy	pdf post cache	Broker Report US/EM/ROW drive earnings for the quarter Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Samvardhana Motherson	Motilal Oswal	137.84	100.00	80.75 (70.70%)	Target met	Buy	pdf post cache	Broker Report Strong performance across businesses Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Mahindra & Mahindra	Motilal Oswal Target	2982.10	1500.00	1281.85 (132.64%)	Target met	Buy	pdf post cache	Broker Report In-line; SUV order book grows despite rise in production Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Info Edge	Motilal Oswal Target	1375.00	4010.00	4197.75 (-67.24%)	Target met	Neutral	pdf post cache	Broker Report Non-IT to partially offset weak IT performance in 1HFY24 Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Grasim Industries	Motilal Oswal Target	2634.80	1940.00	1688.30 (56.06%)	Target met	Buy	pdf post cache	Broker Report Weak performance; gradual recovery expected Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Ashok Leyland	BOB Capital Markets Ltd. Target	221.62	184.00	145.50 (52.32%)	Target met	Buy	pdf post cache	Broker Report Ashok Leyland (BUY): Healthy performance continues BOB Capital Markets Ltd. Q4 volumes grew 23% YoY with realisations up 9%, aiding 33% topline growth to Rs 116bn pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1744.80	1160.00	969.90 (79.89%)	Target met	Buy	pdf post cache	Broker Report Specialty portfolio is amplifying margins ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q4FY23 performance was decent, aided by traction in specialty portfolio, India branded and launch of Revlimid in the US. Specialty business sales contribution had increased to 16.6% in FY23 (14% in FY22) and key assets like Ilumya, Winlevi and Cequa will likely improve the share to 21% by FY25E. pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Consumer Durables	ICICI Securities Limited					Sector Update	pdf post cache	Broker Report I-Sec Consumer Momentum Indicator shows 27% overvaluation driven by Staples ICICI Securities Limited Consumer sector overvaluation in May’23 is at 27% (per I-Sec Consumer Momentum Indicator (ICMI)) versus 22% in Dec’22. Though Staples' demand environment continues to be (relatively) muted, there have been sequential improvement in demand (especially in rural) over the quarters in FY23. pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Grasim Industries	ICICI Securities Limited Target	2634.80	1841.00	1688.30 (56.06%)	Target met	Accumulate	pdf post cache	Broker Report Margins disappoint, but have largely bottomed out ICICI Securities Limited Grasim Industries’ (Grasim) Q4FY23 standalone EBITDA plunged 43% YoY/11% QoQ, being 33% below estimates. VSF margin slipped ~300bps YoY though it recovered 180bps QoQ. As for chemicals segment, margin dipped ~470bps YoY and 350bps QoQ. pdf Copy Link Share on Share on Share on Share on Alert
more loading

New Research Reports

Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.

Pick of the Week:29 May 2023

US/EM/ROW drive earnings for the quarter

Strong performance across businesses

In-line; SUV order book grows despite rise in production

Non-IT to partially offset weak IT performance in 1HFY24

Weak performance; gradual recovery expected

Ashok Leyland (BUY): Healthy performance continues

Specialty portfolio is amplifying margins

I-Sec Consumer Momentum Indicator shows 27% overvaluation driven by Staples

Margins disappoint, but have largely bottomed out

Advisor Screeners